Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Castleman Disease | Research

Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era

Authors: Alexander Suarez, Curran Reilly, David C. Fajgenbaum

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Castleman disease (CD) describes a group of rare and poorly understood lymphoproliferative disorders that include unicentric CD (UCD), Human Herpes Virus-8 (HHV8)-associated multicentric CD (HHV8 + MCD), and HHV8-negative/idiopathic MCD (iMCD). Efforts to advance research and drug discovery for CD have been slowed by challenges shared by other rare diseases, such as collecting and centralizing data and biospecimens for research. To collect disease characteristic data and identify individuals interested in contributing biospecimens for research, a global research organization - the Castleman Disease Collaborative Network (CDCN) - established an international Contact Database and electronic repository (E-repository). Herein, we performed analyses of these datasets to further characterize CD and gain insights into research biospecimen acquisition.

Results

Descriptive statistical analyses were performed on 891 participants from the Contact Database and 166 patients in the E-repository. The median age of patients at the time of enrollment in the Contact Database and E-repository was 42 ± 15.7 and 35 ± 14.8, respectively. The E-repository had increased representation from patients with MCD and the iMCD subtype compared to other sub-groups. Though the majority of participants were from the USA, a total of 49 countries on 6 continents were represented. Several patient characteristics in the Contact Database were associated with subsequent enrollment in the E-repository. There were significantly more MCD patients (p < 0.0001) and females (p = 0.002) enrolled in the E-repository compared to the Contact Database. Patient’s year of birth, date of registration, preferred method of communication, and relationship to the patient were also significantly associated with enrollment in the e-Repository.

Conclusions

This study of the largest- dataset of CD patients worldwide provides insights into disease phenotypes, characteristics of patients interested in contributing data and biospecimens for research, and methods for successfully acquiring data and biospecimens. Generally, the factors associated with enrollment in the E-repository represented severity of disease subtype, proximity to the research, and patient motivation. We hope that these findings and the sample documentation (e.g., electronic consent, recruitment materials) provided with this article will assist future rare disease efforts with overcoming hurdles.
Appendix
Available only for authorised users
Literature
1.
go back to reference Public Law 97-414: To amend the Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions and for other purposes. [Orphan Drug Act]" (96 Stat. 2049; Date: 1/4/83). Text from: United States Public Laws; 1983. Accessed 05 July 2019. Public Law 97-414: To amend the Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions and for other purposes. [Orphan Drug Act]" (96 Stat. 2049; Date: 1/4/83). Text from: United States Public Laws; 1983. Accessed 05 July 2019.
2.
go back to reference Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform. 2011;12(4):346–56.CrossRef Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform. 2011;12(4):346–56.CrossRef
3.
go back to reference Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924–33.CrossRef Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924–33.CrossRef
4.
go back to reference Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–75.CrossRef Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–75.CrossRef
5.
go back to reference Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol. 2016;3(4):e150–2.CrossRef Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol. 2016;3(4):e150–2.CrossRef
6.
go back to reference Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015;56(5):1252–60.CrossRef Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015;56(5):1252–60.CrossRef
8.
go back to reference Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25–35.PubMed Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25–35.PubMed
9.
go back to reference Marcin J. “Castleman Disease: What Is It and How is it Treated?” Healthline; 2017. Marcin J. “Castleman Disease: What Is It and How is it Treated?” Healthline; 2017.
10.
go back to reference Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM. The clinical spectrum of Castleman's disease. Am J Hematol. 2012;87(11):997–1002.CrossRef Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM. The clinical spectrum of Castleman's disease. Am J Hematol. 2012;87(11):997–1002.CrossRef
12.
go back to reference Curtin R, Presser S, Singer E. The effects of response rate changes on the index of consumer sentiment. Public Opin Q. 2000;64(4):413–28.CrossRef Curtin R, Presser S, Singer E. The effects of response rate changes on the index of consumer sentiment. Public Opin Q. 2000;64(4):413–28.CrossRef
13.
go back to reference Rooney PM, Mesch DJ, Chin W, Steinberg KS. The effects of race, gender, and survey methodologies on giving in the US. Econ Lett. 2005;86(2):173–80.CrossRef Rooney PM, Mesch DJ, Chin W, Steinberg KS. The effects of race, gender, and survey methodologies on giving in the US. Econ Lett. 2005;86(2):173–80.CrossRef
14.
go back to reference Boutin NT, Mathieu K, Hoffnagle AG, Allen NL, Castro VM, Morash M, O’Rourke PP, Hohmann EL, Herring N, Bry L, Slaugenhaupt SA. Implementation of electronic consent at a biobank: an opportunity for precision medicine research. J Pers Med. 2016;6(2):17.CrossRef Boutin NT, Mathieu K, Hoffnagle AG, Allen NL, Castro VM, Morash M, O’Rourke PP, Hohmann EL, Herring N, Bry L, Slaugenhaupt SA. Implementation of electronic consent at a biobank: an opportunity for precision medicine research. J Pers Med. 2016;6(2):17.CrossRef
Metadata
Title
Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era
Authors
Alexander Suarez
Curran Reilly
David C. Fajgenbaum
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1145-y

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue